Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker

Journal of Clinical Oncology

Volumn 24, Issue 20, 2006, Pages 3293-3298

  Hylton, Nola ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOXORUBICIN; GADOLINIUM PENTETATE MEGLUMINE; SEMAXANIB; CONTRAST MEDIUM; TUMOR MARKER;

ANGIOGENESIS; BREAST CANCER; CLINICAL TRIAL; CONTRAST ENHANCEMENT; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; METHODOLOGY; NEOPLASM; PHASE 1 CLINICAL TRIAL; PROGNOSIS; PROSPECTIVE STUDY;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS, PHASE I; CONTRAST MEDIA; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33745963117     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.8080     Document Type: Review

References (34)

1. Miller JC, Pien HH, Sahani D, et al: Imaging angiogenesis: Applications and potential for drug development. J Natl Cancer Inst 97:172-187, 2005
2. Padhani AR, Leach MO: Antivascular cancer treatments: Functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 30:324-341, 2005
3. Rehman S, Jayson GC: Molecular imaging of antiangiogenic agents. Oncologist 10:92-103, 2005
4. Weidner N: Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 31:403-405, 2000
5. Evelhoch JL: Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 10:254-259, 1999
6. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
7. Su MY, Cheung YC, Fruehauf JP, et al: Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 18:467-477, 2003
8. Buadu LD, Murakami J, Murayama S, et al: Patterns of peripheral enhancement in breast masses: Correlation of findings on contrast medium enhanced MRI with histologic features and tumor angiogenesis. J Comput Assist Tomogr 21:421430, 1997
9. Buckley DL, Drew PJ, Mussurakis S, et al: Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging 7:461-464, 1997
10. Furman-Haran E, Schechtman E, Kelcz F, et al: Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 104:708-718, 2005
11. Esserman L, Hylton N, George T, et al: Contrast-enhanced magnetic resonance imaging to assess tumor histopathology and angiogenesis in breast carcinoma. Breast J 5:13-21, 1999
12. Ikeda O, Nishimura R, Miyayama H, et al: Evaluation of tumor angiogenesis using dynamic enhanced magnetic resonance imaging: Comparison of plasma vascular endothelial growth factor, hemodynamic, and pharmacokinetic parameters. Acta Radiol 45:446-452, 2004
13. Tuncbilek N, Unlu E, Karakas HM, et al: Evaluation of tumor angiogenesis with contrast-enhanced dynamic magnetic resonance mammography. Breast J 9:403-408, 2003
14. Tuncbilek N, Karakas HM, Altaner S: Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 29:166-172, 2004
15. Matsubayashi R, Matsuo Y, Edakuni G, et al: Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: Correlation of MR findings with histologic features and expression of growth factors. Radiology 217:841-848, 2000
16. Oshida K, Nagashima T, Ueda T, et al: Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. Eur Radiol 15:1353-1360, 2005
17. Padhani AR, Gapinski CJ, Macvicar DA, et al: Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 55:99-109, 2000
18. Schlemmer HP, Merkle J, Grobholz R, et al: Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 14:309-317, 2004
19. Hara N, Okuizumi M, Koike H, et al: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62:140-147, 2005
20. Hawighorst H, Knapstein PG, Weikel W, et al: Angiogenesis of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777-4786, 1997
21. Hawighorst H, Knapstein PG, Knopp MV, et al: Cervical carcinoma: Standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival. Magma 8:55-62, 1999
22. Wang B, Gao ZQ, Yan X: Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol 46:353-358, 2005
23. Lu JP, Wang J, Wang T, et al: Microvessel density of malignant and benign hepatic lesions and MRI evaluation. World J Gastroenterol 10:1730-1734, 2004
24. Fujimoto K, Abe T, Muller NL, et al: Small peripheral pulmonary carcinomas evaluated with dynamic MR imaging: Correlation with tumor vascularity and prognosis. Radiology 227:786-793, 2003
25. Buadu LD, Murakami J, Murayama S, et al: Breast lesions: Correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology 200:639-649, 1996
26. Nagashima T, Suzuki M, Yagata H, et al: Dynamic-enhanced MRI predicts metastatic potential of invasive ductal breast cancer. Breast Cancer 9:226-230, 2002
27. Hulka CA, Edmister WB, Smith BL, et al: Dynamic echo-planar imaging of the breast: Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 205:837-842, 1997
28. Tuncbilek N, Karakas HM, Okten OO: Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol 53:500-505, 2005
29. Kiessling F, Huber PE, Grobholz R, et al: Dynamic magnetic resonance tomography and proton magnetic resonance spectroscopy of prostate cancers in rats treated by radiotherapy. Invest Radiol 39:34-44, 2004
30. Wedam SB, Low JA, Yang SX, et al: Antiangiogenic and antitumor effects of bevacizumab in inflammatory and locally advanced breast cancer patients. J Clin Oncol 24:769-777, 2006
31. Liu G, Rugo HS, Wilding G, et al: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study. J Clin Oncol 23:5464-5473, 2005
32. O'Donnell A, Padhani A, Hayes C, et al: A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer 93:876-883, 2005
33. Morgan B, Thomas AL, Drevs J, et al: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 21:3955-3964, 2003
34. Mross K, Drevs J, Muller M, et al: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41:1291-1299, 2005